Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
15 Julio 2024 - 3:05PM
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company
leveraging novel next-generation sequencing (NGS) and spatial
multiomics technologies to empower researchers and clinicians,
today announced that it received formal notice from the Nasdaq
Stock Market LLC (“Nasdaq”) that the Company has regained
compliance with Nasdaq’s minimum bid price requirement under Nasdaq
Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital
Market.
As previously disclosed, on July 17, 2023, Singular Genomics
received a letter from Nasdaq indicating that the Company was not
in compliance with Nasdaq’s listing requirements because the
closing bid price per share for the Company’s common stock had
closed below $1.00 for the previous 30 consecutive business
days.
As determined by Nasdaq, the closing bid price of the Company’s
common stock was at $1.00 per share or greater for 11 consecutive
days from June 26, 2024 to July 11, 2024. Accordingly, the Company
has regained compliance with Listing Rule 5550(a)(2), and this
matter is now closed.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that
develops next-generation sequencing and multiomics technologies.
The commercially available G4® Sequencing Platform is a powerful,
highly versatile benchtop genomic sequencer designed to produce
fast and accurate results. In addition, the company is currently
developing the G4X™ Spatial Sequencer, which will leverage
Singular’s proprietary sequencing technology, applying it as an in
situ readout for transcriptomics, proteomics and fluorescent
H&E in tissue, with spatial context and on the same platform as
the G4. Singular Genomics’ mission is to empower researchers and
clinicians to advance science and medicine. Visit
www.singulargenomics.com for more information.
Forward-looking Statements
Certain statements contained in this press release, other than
historical information, constitute forward-looking statements
within the meaning of the federal securities laws. Forward-looking
statements include, but are not limited to, statements concerning
expectations regarding the future continued listing on the Nasdaq
Capital Market. In some cases, forward-looking statements can be
identified by terms such as “anticipates,” “believes,” “could,”
“estimates,” “expects,” “foresees,” “forecasts,” “guidance,”
“intends” “goals,” “may,” “might,” “outlook,” “plans,” “potential,”
“predicts,” “projects,” “seeks,” “should,” “targets,” “will,”
“would” or similar expressions and the negatives of those terms.
These forward-looking statements are subject to risks,
uncertainties, and assumptions. If the risks materialize or
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. New
risks emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. Further information on these and additional risks that
could affect Singular Genomics’ results is included in its filings
with the Securities and Exchange Commission (SEC), including its
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q, and future reports that Singular Genomics may file with the
SEC from time to time, which could cause actual results to vary
from expectations. Any forward-looking statement made by Singular
Genomics in this press release speaks only as of the day on which
Singular Genomics makes it. Singular Genomics assumes no obligation
to, and does not currently intend to, update any such
forward-looking statements after the date of this release.
Investor ContactPhilip Trip TaylorGilmartin
Groupir@singulargenomics.com
Media ContactMatt
Browningpr@singulargenomics.com
Singular Genomics Systems (NASDAQ:OMIC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Singular Genomics Systems (NASDAQ:OMIC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024